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Abstract Recently, LiCl has been shown to inhibit amyloid L
peptide secretion in association with diminished glycogen syn-
thase kinase L (GSK3L) activity. However, it remains unclear if
direct inhibition of GSK3L activity will result in decreased AL
production. Frequently rearranged in advanced T-cell lympho-
mas 1 (FRAT1) protein is a negative regulator of GSK3K/L
kinase activity. To examine whether direct inhibition of
GSK3K/L kinase activity can lower AL production, a FRAT1
peptide was expressed in swAPP751 cells that produce high lev-
els of AL. Our data demonstrate that cellular expression of
FRAT1 peptide in swAPP751 cells increases both GSK3K and
L phosphorylation on Ser21 and Ser9, respectively, while inhib-
iting kinase activity of both isoforms. Moreover, as a result of
FRAT1 expression, the production of both total AL and AL142
was signi¢cantly decreased. Thus, we provide evidence that di-
rect regulation of GSK3K/L by FRAT1 peptide signi¢cantly
decreases AL production in swAPP751 cells.
4 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Many believe that the deposition of AL in the brain is an
early and an underlying event in the development of Alzhei-
mer’s disease (AD) [1]. In fact, according to the amyloid
cascade hypothesis, the inhibition of AL production and ac-
cumulation is considered to be a promising therapeutic ap-
proach for treatment of this disease. Indeed, many approaches
have been proposed to inhibit AL production/accumulation
including inhibiting L-secretase [2,3] and Q-secretase [4^6], reg-
ulating ApoE signaling [7,8] and, more recently, applying AL
antibody intervention [9^11].
Glycogen synthase kinases GSK3K/L are serine/theronine-
speci¢c multifunctional protein kinases that are thought to
play an important role in the regulation of a variety of cellular
processes in vivo [12^14]. Indeed, GSK3K/L have been impli-
cated in many signal transduction pathways including PI3
signaling [15] and Wnt signaling cascades [16]. Phosphoryla-
tion of GSK3K/L at N-terminal serine by kinases, like PI3
activated protein kinase B (Akt/PKB), negatively regulates
GSK3K/L kinase activity. However, Wnt signaling results in
the inhibition of GSK3L in a PKB independent fashion. As
demonstrated in Drosphilia, Wnt inhibits GSK3L in a signal-
ing complex with Dvl, GSK binding protein (GBP), axin and
L-catenin [17]. GBP is a positive regulator of Wnt signaling by
negatively regulating GSK3L leading to the stability of L-cat-
enin. Frequently rearranged in advanced T-cell lymphomas 1
(FRAT1) is the mammalian homologue to GBP [18]. GSK3L
have been implicated in the development of AD pathology
[19,20], which has positioned GSK3L as an attractive poten-
tial target for treatment of AD. GSK3K implication in AD
pathology is largely unknown.
FRATs are GSK3K/L binding proteins, composed of three
members, FRAT1, FRAT2 and FRAT3. As components of a
Wnt signaling complex, FRAT1 and 2 can physically bind to
GSK3L and inhibit its kinase activity [17]. FRAT1 and
FRAT2 share a high degree of homology in their C-terminal
region [18]. It has been demonstrated that FRAT peptides
from the conserved C-terminal region in FRAT1 and 2 are
capable of inhibiting GSK3K/L kinase activity by binding to
either GSK3K or L [18].
Many lines of evidence have demonstrated that GSK3L is
involved in the hyperphosphorylation of tau, a classical
pathological feature of AD [21]. In fact, GSK3L is a major
contributor to the phosphorylation of tau [21]. GSK3K/L in-
volvement in AL production, however, is largely unknown. In
order to study e¡ects on APP processing, we expressed a
FRAT1 peptide in swAPP751 stable cells to inhibit GSK3K/L
kinase activity and examined subsequent AL production.
2. Materials and methods
2.1. Cell culture
In this investigation, we used well-characterized high AL producing
HEK293 cells stably transfected with human Swedish APP751 [22],
denoted as swAPP751. The cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM/F12 3:1; Life Technologies, Gaithersburg,
MD, USA) supplemented with 5% fetal bovine serum, 20 mM
HEPES, 50 Wg/ml tobramycin, and 300 Wg/ml G418 and maintained
at 37‡C and 5% CO2.
2.2. Construction of FRAT1 peptide expression vector ^ FRAR1tide
To express a human FRAT1 peptide, the coding DNA sequences
for a 39 amino acid peptide from the C-terminal of human FRAT1
were cloned into a pcDNA3.1-V5-His-TOPO vector (Invitrogen,
Carlsbad, CA, USA) by employing polymerase chain reaction
(PCR) strategies to form an expression vector, designated FRAT1tide
hereafter. Brie£y, two 75-mer oligos were synthesized. Oligo 1 (5PCA-
CCATGTCCCAACCAGAAACCCGCACAGGCGACGACGACC-
CGCACCGGCTTCTGCAGCAGCTAGTGCTCTCTGGAAAC-3P)
is a FRAT1 sense strand containing a start codon (ATG) and partial
FRAT1tide coding sequences of the FRAT1tide N-terminal portion.
Oligo 2 (CTGCAGCCGTCGCGAATGAAGCCTTCGCACGGCC-
TCCTTGATGAGGTTTCCAGAGAGCACTAGCTGCTGCAGA-
AG-3P) is a FRAT1tide antisense strand containing partial FRAT1-
tide coding sequences of the FRAT1tide C-terminal portion. Oligos 1
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and 2 contained 30 bases overlapping in the middle of the FRAT1tide
coding sequences and served as FRAT1tide PCR templates for an-
nealing and extending at the beginning of PCR. Two additional oligos
were synthesized as PCR primers. The forward primer (5PCAC-
CATGTCCCAACCAGAAACCCGCACA-3P) consists of Kozac se-
quences, a start codon and partial 5P-end coding sequences of
FRAT1tide. The reverse primer (5P-CTGCAGCCGTCGCGAAT-
GAAGCCTTCG-3P) covers the 3P-end of FRAT1tide coding sequen-
ces. The PCR products were in-framely cloned into pcDNA3.1/V5-
His-TOPO (Invitrogen) to form FRAT1tide. The V5-tag and His-tag
were included for detecting FRAT1tide expression at the protein level.
2.3. Transfection and Western blot
The FRAT1tide expression vector was transiently transfected into
swAPP751 cells using lipofectamine plus following manufacturer’s in-
struction (Gibco, Charsbad, CA, USA). Western blots were con-
ducted as described previously [23]. Antibodies used in Western blots
against phospho-GSK3K/L, GSK3K/L protein and L-actin were pur-
chased from Cell Signaling Technology (Beverly, MA, USA), Trans-
duction Laboratories (San Diego, CA, USA) and Santa Cruz (Santa
Cruz, CA, USA), respectively.
2.4. AL enzyme-linked immunosorbent assay (ELISA)
Determination of total AL and AL142 was quanti¢ed using a sand-
wich ELISA described previously [24].
2.5. Statistics
All statistical analysis was performed using the Student’s t-test with
a standard P-value threshold of 9 0.05. Data are presented as
meanSS.D.
3. Results
3.1. Expression of FRAT1tide in the swAPP751 cell alters
APP processing
The ¢nal FRAT1tide expression vector contained the fol-
lowing sequences from 5P to 3P : a Kozac sequences, a start
codon (ATG), coding sequences for FRAT1tide, coding se-
quences for V5-tag and His-tag and a stop codon (Fig. 1A).
The FRAT1tide expression vector was transiently transfected
into swAPP751 cells. Forty-eight hours after transfection, cells
were harvested and the resulting cell lysate was subjected to
Western blot analysis using an HRP-V5 antibody (Invitrogen,
Carlsbad, CA, USA). As shown (Fig. 1B), FRAT1tide expres-
sion vector coded a HRP-V5 antibody detected peptide at the
predicted molecular weight in swAPP751 cells.
In this study, the correlation between expression of
FRAT1tide and AL production was addressed using
swAPP751 cells. FRAT1tide transfection experiments were car-
ried out for 48 h. Culture medium and cells were then har-
vested separately. The cell medium was used to examine AL
production. As shown in Fig. 2, FRAT1tide expression sig-
ni¢cantly decreased the production of both total AL (Fig. 2A)
and AL142 (Fig. 2B) in swAPP751 cells at 48 h following
transfection. Overall, total AL production was decreased
more than AL142 production. These data suggest that expres-
sion of FRAT1tide is su⁄cient to decrease AL production in
swAPP751 cells. To con¢rm that the FRAT1tide mediated
decrease in AL production is not due to FRAT1tide expres-
sion related toxicity, swAPP751 MTT cell viability assays were
also carried out at 48 h following transfection. There were no
di¡erences in cell viability between FRAT1tide and vector
transfected cells (data not shown).
3.2. FRAT1tide expression in the swAPP751 cell negatively
modulates GSK3 kinase activity
In order to investigate whether the FRAT1tide expression
mediated decrease in AL production involved direct inhibition
of GSK3K/L kinase activity, GSK3K/L phospho-immunoblot
analysis was conducted. swAPP751 cells were again transfected
with FRAT1tide for 48 h, to correlate with the reduction in
AL levels described above, harvested and subjected to Western
blot analysis with antibodies against phospho-GSK3K on
Ser21 and phospho-GSK3L on Ser9, GSK3K/L protein and
L-actin. As shown in Fig. 3A, expression of FRAT1tide re-
sulted in elevated phosphorylation on both GSK3K and
GSK3L, suggesting negative regulation of these kinases. In
contrast, GSK3K and L protein levels were una¡ected by
FRAT1tide expression (Fig. 3B). L-Actin serves as loading
control (Fig. 3C). The relative di¡erences of phosphorylation
of GSK3K and L were analyzed by quantitative densitometry
(Fig. 3D,E). Since it is known that elevated phosphorylation
on Ser21/9 of GSK3K/L is correlated with decreased kinase
activity, these data suggest that FRAT1tide inhibits GSK3K/L
kinase activity in swAPP751 cells.
Fig. 1. Structure of FRAT1tide expression vector and Western blot
showing the expression of FRAT1tide in swAPP751 cells. Panel A
shows that the FRAT1tide expression vector consists of a start co-
don (ATG), 39 amino acid FRAT1 peptide, V5 epitope and His-
tag. Panel B is a Western blot showing the expression of FRAT1-
tide in swAPP751 cells with the predicted molecular weight, 9.7 kDa.
Lane 1 represents vector control. Lane 2 represents transfected
FRAT1tide.
Fig. 2. Expression of FRAT1tide in swAPP751 cells signi¢cantly de-
creases levels of both total AL and AL142. Results shown represent
three independent experiments. In both panel A and B, V and F1
stand for vector and FRAT1tide, respectively. Panel A shows total
AL levels in the medium harvested 48 h after transfection of vector
or FRAT1tide into swAPP751 cells. The di¡erences of total AL lev-
els between V and F1 are statistically signi¢cant (P6 0.01). Panel B
shows AL142 levels in the medium harvested 48 h after transfection
of vector or FRAT1tide into swAPP751 cells. The di¡erences of
AL142 levels between V and F1 are statistically signi¢cant
(P6 0.05).
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4. Discussion
The goal of this study was to investigate whether direct
inhibition of GSK3K/L kinase activity could lead to a decrease
in AL production. GSK3L is known to hyperphosphorylate
tau and is a component of the wnt signaling cascade where it
is negatively regulated in a complex with FRAT1. However,
there is little evidence that GSK3K/L is involved in AL pro-
duction. Although a recent study showed that lithium inhib-
ited AL production in COS7 cells transiently transfected with
APP C100, suggesting that lithium elicits its e¡ect through
GSK3L [25], there was no direct evidence to implicate
GSK3L. In our studies, however, we used a FRAT1 peptide
derived from the highly conserved C-terminal region of hu-
man FRAT1 that is known to be a selective GSK3K/L inhib-
itor [18]. Using swAPP751 transfected cells, we provide evi-
dence that direct inhibition of GSK3K/L kinase activity by
FRAT1 peptide elicits a decrease in AL production.
Moreover, we observed that phosphorylation of both
GSK3K on Ser21 and GSK3L on Ser9 was robustly increased
by FRAT1tide. This is reasonable because FRAT peptide can
physically interact with both GSK3K and L. Interestingly,
GSK3K was phosphorylated to a higher degree than GSK3L
(more than four-fold) (Fig. 3A), suggesting GSK3K plays an
important role in APP processing. Indeed, this result agrees
with the recent observation that inhibition of GSK3K kinase
activity signi¢cantly inhibits AL production in vitro [26]. It
remains unclear, however, why physically binding of FRAT
peptide to GSK3K/L could increase phosphorylation of
GSK3K and L. Our hypothesis is that the FRAT-GSK3K/L
binding could make the GSK3K/L protein conformation more
accessible to be phosphorylated by upstream kinases or less
accessible to be dephosphorylated by phosphatases. It is well
known that phosphorylation of both GSK3K on Ser21 and
GSK3L on Ser9 negatively regulates GSK3K/L activity. How-
ever, it is conceivable that the phosphorylated GSK3K/L by
FRAT1 peptide may directly participate in the APP process-
ing by forming complexes with several other proteins such as
presenilin [27], a component of the gamma secretase complex.
FRAT1 peptide, a su⁄cient and speci¢c inhibitor for both
GSK3K and L kinase activity, provides a valuable tool to
further understand the relationship between GSK3K/L signal-
ing and AL production. The speci¢c mechanism of how
GSK3K/L is involved in AL production or perhaps plaque
formation warrants further investigation.
Taken together, we conclude that expression of a FRAT1
peptide is su⁄cient to inhibit GSK3K/L kinase activity in
swAPP751 cells while signi¢cantly lowering AL production.
This result is interesting, since FRAT peptides can physically
bind to GSKK and L. To our knowledge, this is the ¢rst
report that shows direct inhibition of GSK3K/L kinase activity
by FRAT1 peptide results in decreased AL production.
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